Adam Dahlberg bought 1 million shares in medical technology company Senzime on 11 November, where he is a board member and a major shareholder. The shares were bought at a price of SEK 3.55 per share, a transaction worth SEK 3.55 million. The transaction was carried out on Nasdaq Stockholm. This is according to the Swedish Financial Supervisory Authority’s insider register.
Dahlberg subsequently owns 9.13 million shares, corresponding to 5.81 percent of the capital and votes in Senzime, according to the shareholder service Holdings.
